Topics

Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS

09:28 EDT 13 Sep 2019 | FinanzNachrichten

THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) said Friday that the Phase 3 CANDOR study evaluating KYPROLIS in combination with dexamethasone and DARZALEX or KdD compared to KYPROLIS and dexamethasone al...

Original Article: Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS

NEXT ARTICLE

More From BioPortfolio on "Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...